Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-054023
Filing Date
2020-11-16
Accepted
2020-11-16 08:00:39
Documents
66
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q scph-10q_20200930.htm 10-Q 2047426
2 EX-10.1 scph-ex101_106.htm EX-10.1 284772
3 EX-31.1 scph-ex311_6.htm EX-31.1 10691
4 EX-32.1 scph-ex321_7.htm EX-32.1 8151
  Complete submission text file 0001564590-20-054023.txt   6912900

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT scph-20200930.xml EX-101.INS 1339005
6 XBRL TAXONOMY EXTENSION SCHEMA scph-20200930.xsd EX-101.SCH 48573
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE scph-20200930_cal.xml EX-101.CAL 47900
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE scph-20200930_def.xml EX-101.DEF 137165
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE scph-20200930_lab.xml EX-101.LAB 389195
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scph-20200930_pre.xml EX-101.PRE 295923
Mailing Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803
Business Address 2400 DISTRICT AVENUE SUITE 310 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

EIN.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38293 | Film No.: 201313739
SIC: 2834 Pharmaceutical Preparations